1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

US FDA Finds Poor Data Integrity At Second Intas Plant

 
• By Bowman Cox

After machines counted particles in vials, workers revised reports so out-of-specification batches could be exported to the US and the EU.

Counting particles in vials
the art of counting particles at intas • Source: Shutterstock

A 12 May 2023 inspection of an Intas Pharmaceuticals Ltd. plant in Sarkhej, a suburb of Ahmedabad, India, has uncovered another stunning display of data manipulation at the firm, according to the US Food and Drug Administration’s 15-observation, 29-page Form 483 report of inspectional observations.

according to the US Food and Drug Administration’s Form 483 report of inspectional observations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Drug Quality Assurance Inspections Closer To Pre-Pandemic Levels, But Still Behind

 
• By Grace Moser

The CDER FY 2024 annual inspections report says the largest inspection increase was in China.

Taiwan To Phase Out Paper Drug Package Inserts By 2027

 
• By Eliza Slawther

Companies that market drugs in Taiwan must submit electronic versions of their package inserts to Taiwan’s drug regulator by the year-end, lawyers say.

Pakistan Adopts Global PIC/S GMP Guidelines In ‘Landmark Regulatory Reform’

 
• By Vibha Sharma

The Drug Regulatory Authority of Pakistan has adopted a new benchmark for good manufacturing practices, ensuring that the quality and safety of medicines produced in Pakistan meet international standards.

Generic Industry Looking For Expanded Inspections As US FDA Rehires Staff

 
• By Grace Moser

Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.

More from Compliance

Pakistan Adopts Global PIC/S GMP Guidelines In ‘Landmark Regulatory Reform’

 
• By Vibha Sharma

The Drug Regulatory Authority of Pakistan has adopted a new benchmark for good manufacturing practices, ensuring that the quality and safety of medicines produced in Pakistan meet international standards.

Generic Industry Looking For Expanded Inspections As US FDA Rehires Staff

 
• By Grace Moser

Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.

US Strategic Reserve Bulking Up: New Order Focuses On API Stockpile

 
• By Laura Helbling

The White House is directing the Health and Human Services Department to replenish stockpiles of active pharmaceutical ingredients for “especially critical” medicines.